Zacks.com on MSN8h
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains ...
Cure Today1d
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
IFLScience1d
FDA Breakthrough Therapy Designation Granted For Promising Rectal Cancer Drug
T he US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab ...
FierceBiotech5d
Omeros antibody improves overall survival by 68% in rare condition, new analysis finds
Omeros is putting up its monoclonal antibody up for FDA approval—again. | Omeros is putting up its monoclonal antibody up for ...
Morningstar15d
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
"Receiving FDA Orphan Drug Designation for azeliragon for the treatment of brain metastasis from breast cancer highlights a continued need for new treatment options for these patients," commented ...
Investing15d
FDA grants breakthrough status to Seres' infection drug
The Breakthrough Therapy designation, which is the second for the company, provides Seres with more intensive FDA guidance and a potentially expedited review process. This comes after the drug ...
The Business Journals16d
Pharma company secures another FDA designation for cancer drug
Cantex received orphan drug designation for Azeliragon from the FDA. Azeliragon targets brain metastasis from breast cancer and other cancers. Orphan drug designation offers tax credits and ...
Stockhouse16d
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
"Receiving FDA Orphan Drug Designation for azeliragon for the treatment of brain metastasis from breast cancer highlights a continued need for new treatment options for these patients," commented ...
Seeking Alpha17d
K92 Mining: Clear Path To Mid-Gold Production Breakthrough With Potential Dip Ahead (Rating Downgrade)
K92 Mining Inc. has been downgraded from a "Buy" to a "Hold" rating due to its current high share price, but concerning the business outlook, this has strengthened. The company's Kainantu Gold ...
Nasdaq19d
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation ... Stoke Therapeutics is currently discussing the path for a global phase III registrational ...